2018, innovations and new economic models

Blockbuster drugs losing patent protection, significant advancements in innovation and major financial issues, the year to come will be fundamental.

In oncology, with the indication expansions for a number of immunotherapies, the development of targeted therapies, and the countless clinical studies testing PD-1/PD-L1 inhibitors in combination with other therapies, deep transformations will occur for cancer therapies and make them even more complex.
Standardizing and optimizing the clinical program will be essential to identify the right patient for the right treatment.

The arrival of generic competitors for highly lucrative drugs is a game-changer in neurology. Drug manufacturers are becoming more interested in psychiatric and neurological conditions and investors have an eye on what may become a financial opportunity in the next years.
2018 will most likely see the launch of new migraine therapies, and developments are awaited in resistant epilepsy.

In rare blood disorders, especially Hemophilia, innovative drugs are expected to shake the market and bring real benefits in patients’ quality and duration of life.

Unfortunately, health care systems will not be able to take advantage of the extraordinary advances in research without considering the expenses.
Therapeutic innovations will have to deal not only with increasing demand but affordability and pharma players will have to consider new economic models.

Not only will drug companies be responsible for delivering innovation, but they will need to play a role in monitoring data transparency and inventing innovative financing models.

Read the full article on PM360 website: HERE